Radiopharm Theranostics selected to present positive RAD101 interim data
RAD101 PET in a U.S. Phase 2b imaging trial showed 93% concordance with MRI across evaluable lesions, and the company says it met the primary endpoint.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.